Hydrocephalus, Normal Pressure
|
0.100 |
Biomarker
|
disease |
BEFREE |
There was a significant increase in aggregate CSF MIF concentration in patients with aSAH versus those with NPH (24.4 ± 19.2 vs 2.3 ± 1.1 ng/ml, p < 0.0002).
|
31585427 |
2019 |
Hydrocephalus, Normal Pressure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Compared with their corresponding controls and unlike patients with He-v, patients with NPH (age ≤ 50 years) had significant increases in CSF protein (241%, p < 0.001), CSF albumin (246%, p < 0.001), CSF IgG (328%, p < 0.001), and CSF:serum IgG (321%, p < 0.001) and CSF:serum albumin (257%, p < 0.001) ratios.
|
31059212 |
2019 |
Hydrocephalus, Normal Pressure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Future research in a larger patient sample will help determine the prospective utility of CSF biomarkers in the evaluation of NPH patients.
|
30937451 |
2019 |
Hydrocephalus, Normal Pressure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Normal pressure hydrocephalus (NPH) is a chronic disorder caused by interrupted CSF absorption or flow.
|
29103634 |
2019 |
Hydrocephalus, Normal Pressure
|
0.100 |
Biomarker
|
disease |
BEFREE |
OBJECTIVEA short-term lumbar drain (LD) trial is commonly used to assess the response of normal pressure hydrocephalus (NPH) patients to CSF diversion.
|
30611143 |
2019 |
Hydrocephalus, Normal Pressure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Altered AQP4 expression is also evident in brain tissue from patients with Alzheimer's disease or normal pressure hydrocephalus; glymphatic MRI scans of patients with normal pressure hydrocephalus show reduced CSF tracer entry and clearance.WHERE NEXT?
|
30353860 |
2018 |
Hydrocephalus, Normal Pressure
|
0.100 |
Biomarker
|
disease |
BEFREE |
The relationship found between ICP and Rout provides indirect evidence to support disturbed Cerebrospinal fluid circulation as a key factor in disturbed CSF dynamics in NPH.
|
29520439 |
2018 |
Hydrocephalus, Normal Pressure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Shunt-treated normal pressure hydrocephalus (NPH) is a model for testing whether the increase (time from disease onset to CSF shunt placement, i.e., "protection period") and decrease (time from shunt placement to observation, i.e., "exposure period") in intracranial pressure (ICP) are glaucoma protective or risk factors, respectively.
|
29148901 |
2018 |
Hydrocephalus, Normal Pressure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although there are articles that have discovered several cerebrospinal fluid (CSF) protein biomarkers associated with NPH; however, studies examining individual and total protein concentrations from the ventricular CSF before and after shunting surgery are lacking.
|
29408782 |
2018 |
Hydrocephalus, Normal Pressure
|
0.100 |
Biomarker
|
disease |
BEFREE |
The purpose of this study is to detect whether the volume of CSF removed from patients undergoing high-volume diagnostic lumbar tap test for normal pressure hydrocephalus is significantly associated with post-lumbar tap gait performance.
|
28473344 |
2017 |
Hydrocephalus, Normal Pressure
|
0.100 |
Biomarker
|
disease |
BEFREE |
CSF tapping also improves mental imagery of gait in normal pressure hydrocephalus.
|
28744590 |
2017 |